Latest Industry News & Trends
Market Scope provides comprehensive coverage of the ophthalmic market. Our news stories are a combination of public and proprietary content ranging from coverage of international meetings, surgeon survey results and trends, analysis of company financial reports and public medical registries, press releases, and interviews with executives. Register today to receive free weekly email updates, our top data chart, surgeon poll results, and much more. Locked content can be accessed through a subscription to our ophthalmic industry newsletters.
Cell Therapy News
OpRegen’s Phase I/IIa Trial in GA Shows Mean Improvement in VA Through 36 Months
Lineage Cell Therapeutics reported on June 23 that patients with geographic atrophy who were treated with OpRegen cell therapy in a Phase I/IIa clinical study showed mean improvement in visual acui...
Clinical Trial Updates for Ophthalmic Candidates, July 2025
Market Scope is tracking companies that have announced clinical trial updates or milestone achievements.
Emerging Companies Pursuing Ophthalmic Indications, July 2025
Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.
July 2025 Ophthalmic News Briefs
Hoya Vision Care announced June 2 that it had acquired Centennial Optical, a Canadian distributor of ophthalmic frames, eyeglass lenses, sunglasses, lab supplies, and optical accessories. Financial...
EVs in Ophthalmology Are All About Disease, Not Driving
EVs are having a moment in ophthalmology, and it has nothing to do with Elon Musk. The EVs that are riveting observers in ophthalmology are extracellular vesicles, and according to Sun Young Lee MD...
Emerging Companies Pursuing Ophthalmic Indications, June 2025
Market Scope is tracking companies that have announced new candidates to diagnose and treat eye disease.
New Scleral Clamp Allows Delivery of Two Cell Grafts in Same Eye for Comparing Effects
Scientists with the National Institutes of Health have shown that a new surgical technique can successfully deliver two cell grafts in adjacent subretinal locations in the same eye—allowing direct ...
GA Patients in Eyestem Cell Therapy Trial Show Significant Improvement
India’s Eyestem Research reported April 15 that patients with geographic atrophy (GA) in a Phase I trial of its Eyecyte-RPE cell therapy saw significant vision improvement. Eyecyte-RPE is a cryopre...
Aurion Biotech Appoints Edward J. Holland, MD, as Chief Medical Officer
Aurion Biotech announced April 23 that it had appointed Edward J. Holland, MD, as chief medical officer. Aurion’s lead asset is AURN001, being developed for corneal edema secondary to corneal endot...
GA Patients in Eyestem Phase I Cell Therapy Trial Show Significant Vision Improvement
India’s Eyestem Research reported April 15 that patients with geographic atrophy (GA) in a Phase I trial of its Eyecyte-RPE cell therapy saw significant vision improvement. Eyecyte-RPE is a cryopre...
Alcon Announces Majority Ownership of Aurion Cell Therapy Company
Alcon announced March 26 that it had acquired a majority interest in Aurion Biotech, developer of a corneal cell therapy. News of Alcon’s majority stake—after acquiring additional shares in Aurion ...
Alcon Announces Majority Ownership of Aurion
Alcon announced March 26 that it had acquired a majority interest in Aurion Biotech, developer of a corneal cell therapy. News of Alcon’s majority stake—after acquiring additional shares in Aurion ...
US FDA Approves Neurotech’s Cell Therapy Implant for MacTel
Neurotech Pharmaceuticals announced March 6 that the US FDA had approved Encelto, an encapsulated cell therapy implant to treat macular telangiectasia (MacTel) type 2. It’s the first FDA-approved t...
Deerfield Sues Alcon over Latest Moves to Prevent Aurion IPO
Deerfield Management has filed a lawsuit against an Alcon subsidiary, seeking to prevent Alcon from interfering with Aurion Biotech’s ability to launch an initial public offering. The lawsuit, file...
US FDA Grants RMAT Designation for Luxa’s Dry AMD Cell Therapy Candidate
Luxa Biotechnology, a joint venture between Korea’s Y2 Solutions and the Neural Stem Cell Institute in Rensselaer, New York, announced Feb. 18 that the US FDA had granted regenerative medicine adva...
Want to Read the Full Article?
Already Have an Account?
Register A Corporate Account
A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.